
Our @CULymphoma lead Dr. @mana1981 and @CUInternalMed chief Dr. @vpizzuti44 contributed to a multicenter study on CAR-T vs ASCT in second-line PMBCL, now published @BloodAdvances. #lymsm #bmtsm ashpublications.org/bloodadv…
HematoOncologist, eternal optimist, passionate about making every moment count

Our @CULymphoma lead Dr. @mana1981 and @CUInternalMed chief Dr. @vpizzuti44 contributed to a multicenter study on CAR-T vs ASCT in second-line PMBCL, now published @BloodAdvances. #lymsm #bmtsm ashpublications.org/bloodadv…

Love working with this diverse group of #lymsm clinician-scientists at @CUAnschutz @CUHematology! We are looking forward to seeing you all at @ASH_hematology #ASH26. cc @mana1981 @BradHaverkos @StevenBairMD @cduarte8490
It's been a busy year for our @CULymphoma faculty! Let's preview our abstracts and presentations at the upcoming @ASH_hematology #ASH26 Annual Meeting in December! First, Dr. @mana1981 is giving a prestigious Education Program talk on non-T-cell engaging therapies for FL. #lymsm

Congratulations to our junior @CUHematology faculty on publication of this multicenter study comparing survival and time toxicity outcomes between CAR-T and bispecific antibodies in follicular lymphoma! #lymsm #tcellrx cc @BloodPortfolio @CUMedicalSchool @CUAnschutz
Excited to share our new @BloodPortfolio manuscript comparing CAR-T vs BsAb in R/R FL. In addition to comparing survival, we also studied "time toxicity," or how much time patients spend physically interacting with the healthcare system. #lymsm 🧵 ashpublications.org/bloodadv…

Our @CULymphoma lead Dr. @mana1981 just published a claims data analysis @BloodAdvances on CAR-T referral patterns in the United States. #lymsm #tcellrx pubmed.ncbi.nlm.nih.gov/4295…
Big dreams, bold ideas, and a proud sister cheering from the sidelines! ❤️ Congratulations to my brother @karan_martian on launching UnderLife.ai. Distributed SuperIntelligence in Multi-Agent Worlds youtu.be/dlsCU2q_-5M?is=tqT4… via @YouTube

Just published in @BloodAdvances! "CAR T-cell therapy referral patterns and utilization for relapsed/refractory large B-cell lymphoma in the United States" Only ~15% of patients receive CAR T. We need to continue generating data, raising awareness, and improving access and utilization. ashpublications.org/bloodadv… Thanks to all the authors and collaborators at @bmsnews @lymphomaphilia @KrishPatelMD @LNastoupilMD @mana1981

Our T-cell lymphoma expert @CUAnschutz Dr. @BradHaverkos was interviewed on the @mghpetal #podcast about MRD monitoring in PTCL. #lymsm YouTube: youtu.be/0OcU_FcZph4 Spotify: spotifycreators-web.app.link… Apple: podcasts.apple.com/us/podcas…
On the PETAL Podcast, host @yumengzhang2009 of @MoffittNews, discusses molecular residual disease monitoring in peripheral T-cell lymphoma with Dr. Brad Haverkos of @CUSystem. 🌸 Listen now: youtu.be/0OcU_FcZph4 Also available on Spotify & Apple Podcasts.

Our @CUHematology program (@StevenBairMD @BradHaverkos @mana1981) just published a phase I trial of a homegrown CD19 CAR-T product which we manufacture on campus @CUAnschutz. #lymsm pubmed.ncbi.nlm.nih.gov/4224…
Looking forward to this year’s Lymphoma Research Foundation Educational Forum! Honored to co-chair the program and excited for two days of meaningful education, discussion, and updates for our lymphoma community. Hope you can join us! @lymphoma @WomenInLymphoma @CUCancerCenter
The Educational Forum is a virtual two-day conference with important information about diagnosis and treatment, clinical trials, research advances and how to manage their disease. Date: Sat. Oct 10 – Sun. Oct 11 Find more info and register: bit.ly/4hdNA47

#IMS26 love this analogy by @YiLinMDPhD at the meeting 🤣 Some would say “Work hard, play hard” as we work as a field to cure myeloma… but I now prefer “Immune fitness & reconstitution” instead!! Plus shoutout to @HealthTree #WoMMen hike @GKaurMD et al!

Our @CULymphoma faculty Drs. @mana1981 & @majorajay were featured in this year's @CUDeptMedicine Annual Report. Lymphoma physicians represent! #lymsm
Our FY2026 Annual Report is officially live! 🎉 Rising Above: From Discovery to Care highlights the people, discoveries, and advances shaping the CU Anschutz Department of Medicine. Explore the stories and milestones from across our department. 💙 bit.ly/4y3GUwX

TP53mut LBCL outcomes by tx modality @cduarte8490 @e_JHaem: - 183 pts, 78% DLBCL, 58% stage IV, 72% extranodal dz, 75% int/high IPI - overall: 2-yr PFS 53%, OS 76% - no benefit escalated 1L CIT - no OS difference by 2L/3L approach - DHL: better 2L PFS w/ CAR - 3L CAR/ASCT better PFS in DLBCL TP53 status alone not enough as biomarker for tx-selection in LBCL. TP53mut still can be cured. #lymsm doi.org/10.1111/ejh.70330

🎧 NEW podcast alert! In this week's episode, we're joined by Manali Kamdar (@mana1981), who discusses the use of BTK inhibitors for #NonHodgkinLymphoma in clinical practice. Dr Kamdar provides valuable advice on patient selection, adverse event management, response monitoring, and more.🩺🩸 Click here to listen now: 👉 ow.ly/3ASj50ZMx3O 👈 #Lymphoma #LYMsm #MantleCellLymphoma #DLBCL #HemOnc @CULymphoma @CUMedicalSchool

Our @CULymphoma lead Dr. @mana1981 just published a review on sequencing CD19-targeted therapies in LBCL. #lymsm sciencedirect.com/science/ar… cc @MediHumdani @heMEGirl_MD @gloria_iacoboni

Our @CULymphoma faculty Dr. @majorajay and @CUDeptMedicine chief resident Dr. @vpizzuti44 were featured in a @CUCancerCenter article about their recent study of quality of life after CAR T-cell therapy. #lymsm #mmsm
In a new study, Ajay Major (@majorajay), MD, MBA, and Vincenzo Pizzuti, MD, MS, have tracked a group of blood cancer patients using multiple surveys over the course of two years to see how CAR T-cell therapy impacts their health-related quality of life: bit.ly/3UzIYxF

Article link here: pubmed.ncbi.nlm.nih.gov/4261…